These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32759967)

  • 21. Lymphopenia in COVID-19: Therapeutic opportunities.
    Fathi N; Rezaei N
    Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.
    Abid MB; Mughal M; Abid MA
    JAMA Oncol; 2020 Oct; 6(10):1529-1530. PubMed ID: 32433719
    [No Abstract]   [Full Text] [Related]  

  • 23. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.
    Sette A; Crotty S
    Nat Rev Immunol; 2020 Aug; 20(8):457-458. PubMed ID: 32636479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Privileges and Immunity Certification During the COVID-19 Pandemic.
    Hall MA; Studdert DM
    JAMA; 2020 Jun; 323(22):2243-2244. PubMed ID: 32374358
    [No Abstract]   [Full Text] [Related]  

  • 25. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
    Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
    [No Abstract]   [Full Text] [Related]  

  • 26. COVID-19 and post-traumatic stress disorder: A vicious circle involving immunosuppression.
    Liang X; Zhu Y; Fang Y
    CNS Neurosci Ther; 2020 Aug; 26(8):876-878. PubMed ID: 32678521
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunology of COVID-19: Current State of the Science.
    Vabret N; Britton GJ; Gruber C; Hegde S; Kim J; Kuksin M; Levantovsky R; Malle L; Moreira A; Park MD; Pia L; Risson E; Saffern M; Salomé B; Esai Selvan M; Spindler MP; Tan J; van der Heide V; Gregory JK; Alexandropoulos K; Bhardwaj N; Brown BD; Greenbaum B; Gümüş ZH; Homann D; Horowitz A; Kamphorst AO; Curotto de Lafaille MA; Mehandru S; Merad M; Samstein RM;
    Immunity; 2020 Jun; 52(6):910-941. PubMed ID: 32505227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.
    Kirkcaldy RD; King BA; Brooks JT
    JAMA; 2020 Jun; 323(22):2245-2246. PubMed ID: 32391855
    [No Abstract]   [Full Text] [Related]  

  • 29. Cellular immune responses to covid-19.
    Sewell HF; Agius RM; Stewart M; Kendrick D
    BMJ; 2020 Jul; 370():m3018. PubMed ID: 32737031
    [No Abstract]   [Full Text] [Related]  

  • 30. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
    Ledford H
    Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
    [No Abstract]   [Full Text] [Related]  

  • 31. Establishing a Unified COVID-19 "Immunome": Integrating Coronavirus Pathogenesis and Host Immunopathology.
    Wauters E; Thevissen K; Wouters C; Bosisio FM; De Smet F; Gunst J; Humblet-Baron S; Lambrechts D; Liston A; Matthys P; Neyts J; Proost P; Weynand B; Wauters J; Tejpar S; Garg AD
    Front Immunol; 2020; 11():1642. PubMed ID: 32719686
    [No Abstract]   [Full Text] [Related]  

  • 32. Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Apr; 382(16):e58. PubMed ID: 32320592
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapies for COVID-19: lessons learned from sepsis.
    Remy KE; Brakenridge SC; Francois B; Daix T; Deutschman CS; Monneret G; Jeannet R; Laterre PF; Hotchkiss RS; Moldawer LL
    Lancet Respir Med; 2020 Oct; 8(10):946-949. PubMed ID: 32444269
    [No Abstract]   [Full Text] [Related]  

  • 34. Early Insights into Immune Responses during COVID-19.
    St John AL; Rathore APS
    J Immunol; 2020 Aug; 205(3):555-564. PubMed ID: 32513850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [COVID-19- what have we learned and where are we heading?].
    Gudnason T
    Laeknabladid; 2020 Oct; 106(10):449. PubMed ID: 32991305
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
    Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
    mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronavirus reinfections: three questions scientists are asking.
    Ledford H
    Nature; 2020 Sep; 585(7824):168-169. PubMed ID: 32887957
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19 antibodies on trial.
    DeFrancesco L
    Nat Biotechnol; 2020 Nov; 38(11):1242-1252. PubMed ID: 33087898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19.
    García LF
    Front Immunol; 2020; 11():1441. PubMed ID: 32612615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
    Jiang S; Hillyer C; Du L
    Trends Immunol; 2020 May; 41(5):355-359. PubMed ID: 32249063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.